Literature DB >> 12459106

[Serological testing and prevalence of human immunodeficiency, hepatitis B and C viruses infections amongst acute psychiatric inpatients].

Emilio Fernández-Egea1, Esther Gómez Gil, Bàrbara Corbella Santomà, Manuel Salamero Baró, Jordi Blanch Andreu, Manuel Valdés Miyar.   

Abstract

BACKGROUND AND
OBJECTIVE: The request for serological tests for HIV, HBV and HCV is usual amongst acute psychiatric inpatients. Nevertheless, the seroprevalence and the repercussion of a positive result have been scarcely studied. PATIENTS AND
METHOD: Serological requests for these viruses were retrospectively analyzed in a sample of 332 psychiatric inpatients.
RESULTS: Serological tests were requested by 65.3% patients. The prevalence of any seropositivity was 7.3%: 1.4% were infected by HIV-I, 3.2% had been in contact with HBV but none had an active infection, and 5.1% were infected by HCV. The presence of a positive result did not change the psychiatric therapeutic approach in any case.
CONCLUSIONS: The low prevalence of seropositivity suggests that such tests should be performed selectively in patients who present risk factors or atypical psychiatric symptoms.

Entities:  

Mesh:

Year:  2002        PMID: 12459106     DOI: 10.1016/s0025-7753(02)73543-4

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  2 in total

1.  Characteristics of HCV positive patients in an Italian urban psychiatric unit.

Authors:  Michele Raja; Antonella Azzoni; Daniela Pucci
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-10-01

2.  Undertreatment of human immunodeficiency virus in psychiatric inpatients: a cross-sectional study of seroprevalence and associated factors.

Authors:  Miguel Angel Gonzalez-Torres; Miguel Angel Salazar; Manuel Imaz; Lucía Inchausti; Berta Ibañez; Aranzazu Fernandez-Rivas; Javier Pastor; Bosco Anguiano; Pedro Muñoz; Eduardo Ruiz; Rodrigo Oraa; Sonia Bustamante; Sofia Alvarez de Eulate; Ramón Cisterna
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-11       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.